Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

Expert Review of Proteomics, published by TAYLOR & FRANCIS LTD, is a distinguished journal that focuses on the latest advancements in the field of proteomics, a critical area within biochemistry and molecular biology. With an ISSN of 1478-9450 and E-ISSN 1744-8387, this journal has been pivotal in disseminating high-quality research from its inception in 2004 to its planned convergence in 2024. Its influential position is reflected in its 2023 rankings, placing it in the Q2 category for both Biochemistry and Molecular Biology, alongside respectable Scopus rankings that rank it 118th and 141st in its respective categories. Despite its non-open access structure, Expert Review of Proteomics provides researchers and professionals with a vital platform for critical reviews and insights into proteomic methodologies, thus contributing significantly to the global scientific community. By bridging theoretical research with practical applications, it serves as an essential resource for those dedicated to advancing their knowledge and expertise in this dynamic field.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Cold Spring Harbor Perspectives in Medicine is a premier academic journal published by the esteemed COLD SPRING HARBOR LAB PRESS that has become a crucial resource in the fields of Biochemistry, Genetics, and Medicine. With an impressive impact factor and consistently ranked in the Q1 quartile for both biochemistry and general medicine—as evidenced by its Scopus rankings of #21 and #26 respectively—this journal serves as an essential platform for disseminating high-quality research and comprehensive reviews from leading experts. Covering a convergence of knowledge spanning from 2011 through 2024, it plays a vital role in advancing the understanding of medical science. Researchers, professionals, and students alike benefit from Cold Spring Harbor Perspectives in Medicine, which offers a depth of insight into critical topics, emerging trends, and essential developments within the medical community. Join the conversation and contribute to the ongoing dialogue that drives innovation and excellence in medical research.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.